These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9556166)

  • 21. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy.
    Löscher W; Nau H; Siemes H
    Epilepsia; 1988; 29(3):311-6. PubMed ID: 3131137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients].
    Chen ZJ; Wang XD; Zhou LM; Fang ZY; Wang HS; Li JL; Zhou JQ; Huang HB; Huang M
    Yao Xue Xue Bao; 2014 Apr; 49(4):530-4. PubMed ID: 24974473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous Determination of Valproic Acid and Its Major Metabolites by UHPLC-MS/MS in Chinese Patients: Application to Therapeutic Drug Monitoring.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    J Chromatogr Sci; 2017 Apr; 55(4):436-444. PubMed ID: 27993840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
    Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of aspirin on valproic acid metabolism.
    Abbott FS; Kassam J; Orr JM; Farrell K
    Clin Pharmacol Ther; 1986 Jul; 40(1):94-100. PubMed ID: 3087680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine.
    Cansu A; Serdaroglu A; Biberoglu G; Tumer L; Hirfanoglu TL; Ezgu FS; Hasanoglu A
    Epileptic Disord; 2011 Dec; 13(4):394-400. PubMed ID: 22258044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.
    Yokogawa K; Iwashita S; Kubota A; Sasaki Y; Ishizaki J; Kawahara M; Matsushita R; Kimura K; Ichimura F; Miyamoto K
    Pharm Res; 2001 Sep; 18(9):1320-6. PubMed ID: 11683247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empirical approach for improved estimation of unbound serum concentrations of valproic acid in epileptic infants by considering their physical development.
    Ueshima S; Aiba T; Sato T; Matsunaga H; Kurosaki Y; Ohtsuka Y; Sendo T
    Biol Pharm Bull; 2011; 34(1):108-13. PubMed ID: 21212527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between valproic acid and carbapenem antibiotics.
    Mori H; Takahashi K; Mizutani T
    Drug Metab Rev; 2007; 39(4):647-57. PubMed ID: 18058328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of valproic acid and its metabolites using gas chromatography with mass-selective detection: application to serum and urine samples from sheep.
    Yu D; Gordon JD; Zheng J; Panesar SK; Riggs KW; Rurak DW; Abbott FS
    J Chromatogr B Biomed Appl; 1995 Apr; 666(2):269-81. PubMed ID: 7633603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy.
    Gidal BE; Pitterle ME; Spencer NW; Maly MM
    J Clin Pharm Ther; 1995 Aug; 20(4):215-9. PubMed ID: 8557785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxidative stress in children receiving valproic acid.
    Michoulas A; Tong V; Teng XW; Chang TK; Abbott FS; Farrell K
    J Pediatr; 2006 Nov; 149(5):692-6. PubMed ID: 17095346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.
    Itoh H; Suzuki Y; Fujisaki K; Sato Y; Takeyama M
    Biol Pharm Bull; 2012; 35(6):971-4. PubMed ID: 22687541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carnitine disposition before and during valproate therapy in patients with epilepsy.
    Riva R; Albani F; Gobbi G; Santucci M; Baruzzi A
    Epilepsia; 1993; 34(1):184-7. PubMed ID: 8422857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China.
    Feng W; Mei S; Zhu L; Yu Y; Yang W; Gao B; Wu X; Zhao Z; Fang F
    Ther Drug Monit; 2016 Dec; 38(6):738-743. PubMed ID: 27855134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in the renal excretion of valproate and its metabolites after chronic treatment.
    Fisher JE; Nau H; Löscher W
    Epilepsia; 1991; 32(1):146-50. PubMed ID: 1985825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Influencing Sodium Valproate Serum Concentrations in Patients with Epilepsy Based on Logistic Regression Analysis.
    Lan X; Mo K; Nong L; He Y; Sun Y
    Med Sci Monit; 2021 Nov; 27():e934275. PubMed ID: 34776507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy.
    Nasreddine W; Dirani M; Atweh S; Makki A; Beydoun A
    Seizure; 2018 Jul; 59():24-27. PubMed ID: 29730272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
    Chung S; Choi J; Hyun T; Rha Y; Bae C
    J Korean Med Sci; 1997 Dec; 12(6):553-8. PubMed ID: 9443096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.